Biocon receives Health Canada approval for two biosimilars - Bosaya' and Vezuo'

India, April 21 -- Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya' (denosumab), a biosimilar to Prolia', and Vezuo' (denosumab), a biosimilar to Xgeva', on 03 April 2026. Both biosimilars were approved in the most common presentations: BOSAYA, as a 60 mg/mL injection for subcutaneous use in a prefilled syringe; and VEVZUO, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.

Published by HT Digital Content Services with permission from Pivotal Sources....